Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. more
Time Frame | RNA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -13.72% | -2.06% | -0.55% |
1-Month Return | -25.76% | -1.92% | 2.72% |
3-Month Return | -31.21% | -10.4% | 7.66% |
6-Month Return | -19.91% | -4.6% | 10.15% |
1-Year Return | 250.46% | 4.06% | 27.53% |
3-Year Return | 29.59% | 1.94% | 32.31% |
5-Year Return | 7.72% | 36.48% | 89.2% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 2.32M | 6.79M | 9.33M | 9.22M | 9.56M | [{"date":"2019-12-31","value":24.26,"profit":true},{"date":"2020-12-31","value":70.99,"profit":true},{"date":"2021-12-31","value":97.55,"profit":true},{"date":"2022-12-31","value":96.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 14.54M | 37.60M | 639.00K | 1.39M | 2.10M | [{"date":"2019-12-31","value":38.67,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":1.7,"profit":true},{"date":"2022-12-31","value":3.69,"profit":true},{"date":"2023-12-31","value":5.59,"profit":true}] |
Gross Profit | (12.22M) | 6.79M | 9.33M | 9.22M | 7.46M | [{"date":"2019-12-31","value":-131.03,"profit":false},{"date":"2020-12-31","value":72.78,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.91,"profit":true},{"date":"2023-12-31","value":79.98,"profit":true}] |
Gross Margin | (526.95%) | 100.00% | 100.00% | 100.00% | 78.02% | [{"date":"2019-12-31","value":-526.95,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":78.02,"profit":true}] |
Operating Expenses | 19.65M | 51.06M | 127.38M | 188.14M | 245.16M | [{"date":"2019-12-31","value":8.02,"profit":true},{"date":"2020-12-31","value":20.83,"profit":true},{"date":"2021-12-31","value":51.96,"profit":true},{"date":"2022-12-31","value":76.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (17.33M) | (44.28M) | (118.05M) | (178.91M) | (235.60M) | [{"date":"2019-12-31","value":-1733200000,"profit":false},{"date":"2020-12-31","value":-4427700000,"profit":false},{"date":"2021-12-31","value":-11805100000,"profit":false},{"date":"2022-12-31","value":-17891300000,"profit":false},{"date":"2023-12-31","value":-23559800000,"profit":false}] |
Total Non-Operating Income/Expense | (14.79M) | (81.00K) | 146.00K | 9.89M | 43.72M | [{"date":"2019-12-31","value":-33.83,"profit":false},{"date":"2020-12-31","value":-0.19,"profit":false},{"date":"2021-12-31","value":0.33,"profit":true},{"date":"2022-12-31","value":22.63,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (24.73M) | (44.35M) | (118.01M) | (174.00M) | (212.22M) | [{"date":"2019-12-31","value":-2473400000,"profit":false},{"date":"2020-12-31","value":-4435500000,"profit":false},{"date":"2021-12-31","value":-11800900000,"profit":false},{"date":"2022-12-31","value":-17399500000,"profit":false},{"date":"2023-12-31","value":-21222000000,"profit":false}] |
Income Taxes | 7.39M | (373.00K) | (639.00K) | (4.92M) | 1.93M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-5.05,"profit":false},{"date":"2021-12-31","value":-8.65,"profit":false},{"date":"2022-12-31","value":-66.58,"profit":false},{"date":"2023-12-31","value":26.17,"profit":true}] |
Income After Taxes | (32.12M) | (43.98M) | (117.37M) | (169.08M) | (214.15M) | [{"date":"2019-12-31","value":-3212100000,"profit":false},{"date":"2020-12-31","value":-4398200000,"profit":false},{"date":"2021-12-31","value":-11737000000,"profit":false},{"date":"2022-12-31","value":-16907700000,"profit":false},{"date":"2023-12-31","value":-21415310500,"profit":false}] |
Income From Continuous Operations | (24.73M) | (44.35M) | (118.01M) | (174.00M) | (202.25M) | [{"date":"2019-12-31","value":-2473400000,"profit":false},{"date":"2020-12-31","value":-4435500000,"profit":false},{"date":"2021-12-31","value":-11800900000,"profit":false},{"date":"2022-12-31","value":-17399500000,"profit":false},{"date":"2023-12-31","value":-20224800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (32.12M) | (43.98M) | (117.37M) | (169.08M) | (212.22M) | [{"date":"2019-12-31","value":-3212100000,"profit":false},{"date":"2020-12-31","value":-4398200000,"profit":false},{"date":"2021-12-31","value":-11737000000,"profit":false},{"date":"2022-12-31","value":-16907700000,"profit":false},{"date":"2023-12-31","value":-21222000000,"profit":false}] |
EPS (Diluted) | - | (2.85) | (2.84) | (3.33) | (2.90) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-285,"profit":false},{"date":"2021-12-31","value":-284,"profit":false},{"date":"2022-12-31","value":-333,"profit":false},{"date":"2023-12-31","value":-290,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RNA | |
---|---|
Cash Ratio | 17.39 |
Current Ratio | 17.76 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RNA | |
---|---|
ROA (LTM) | -18.33% |
ROE (LTM) | -27.76% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RNA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.08 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.92 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RNA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 386.10 |
P/B | 2.60 |
Price/FCF | NM |
EV/R | 229.83 |
EV/Ebitda | NM |
PEG | NM |
Avidity Biosciences Inc (RNA) share price today is $30.7
Yes, Indians can buy shares of Avidity Biosciences Inc (RNA) on Vested. To buy Avidity Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RNA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Avidity Biosciences Inc (RNA) via the Vested app. You can start investing in Avidity Biosciences Inc (RNA) with a minimum investment of $1.
You can invest in shares of Avidity Biosciences Inc (RNA) via Vested in three simple steps:
The 52-week high price of Avidity Biosciences Inc (RNA) is $56. The 52-week low price of Avidity Biosciences Inc (RNA) is $8.49.
The price-to-earnings (P/E) ratio of Avidity Biosciences Inc (RNA) is
The price-to-book (P/B) ratio of Avidity Biosciences Inc (RNA) is 2.60
The dividend yield of Avidity Biosciences Inc (RNA) is 0.00%
The market capitalization of Avidity Biosciences Inc (RNA) is $3.91B
The stock symbol (or ticker) of Avidity Biosciences Inc is RNA